CoChat
Sign Up
Cited by 178

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

E6 Oncoprotein Represses p53-Dependent Gene Activation via Inhibition of Protein Acetylation Independently of Inducing p53 Degradation

Thomas, Mary C., Chiang, Cheng-Ming·2005·Molecular Cell
DOI 10.1016/j.molcel.2004.12.016
Open this paper in CoChat — free account

Abstract

The mechanism employed by DNA tumor viruses to inhibit p53-dependent transcription from chromatin is poorly understood. Here, we use in vitro-reconstituted chromatin and UV-irradiated cells to define the mechanism of human papillomavirus E6 oncoprotein in repressing p53-dependent transcription. We demonstrate that E6 does not prevent p53 or p300 recruitment to the chromatin but inhibits p300-mediated acetylation on p53 and nucleosomal core histones. This suppression of protein acetylation requires the E6-interacting regions of p300. Moreover, E6 mutants unable to interact with p53 or p300, but not deficient in inducing p53 degradation, fail to inhibit p53-mediated activation, indicating that a p53-E6-p300-containing protein complex is critical for repressing p53-targeted gene activation. That E6 acts as a molecular switch converting p53-p300 from an activating complex to a repressing entity on the chromatin, which occurs independently of E6AP-mediated protein degradation pathway, may represent a general mechanism for gene regulation.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.molcel.2004.12.016

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 60

  1. Avantaggiati, 1997, Recruitment of p300/CBP in p53-dependent signal pathways, Cell, 89, 1175, 10.1016/S0092-8674(00)80304-9 · DOI
  2. Barlev, 2003, A novel human Ada2 homologue functions with Gcn5 or Brg1 to coactivate transcription, Mol. Cell. Biol., 23, 6944, 10.1128/MCB.23.19.6944-6957.2003 · DOI
  3. Boube, 2002, Evidence for a mediator of RNA polymerase II transcriptional regulation conserved from yeast to man, Cell, 110, 143, 10.1016/S0092-8674(02)00830-9 · DOI
  4. Burke, 2000, Co-repressors 2000, FASEB J., 14, 1876, 10.1096/fj.99-0943rev · DOI
  5. Burley, 1998, TATA box mimicry by TFIID, Cell, 94, 551, 10.1016/S0092-8674(00)81596-2 · DOI
  6. Chenna, 2003, Multiple sequence alignment with the Clustal series of programs, Nucleic Acids Res., 31, 3497, 10.1093/nar/gkg500 · DOI
  7. Chiang, 1993, Expression and purification of general transcription factors by FLAG epitope-tagging and peptide elution, Pept. Res., 6, 62
  8. Ciechanover, 1998, The ubiquitin-proteasome pathway, EMBO J., 17, 7151, 10.1093/emboj/17.24.7151 · DOI
  9. Crook, 1991, Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation, Cell, 67, 547, 10.1016/0092-8674(91)90529-8 · DOI
  10. Deckert, 2002, Targeted recruitment of Rpd3 histone deacetylase represses transcription by inhibiting recruitment of Swi/Snf, SAGA, and TATA binding protein, Mol. Cell. Biol., 22, 6458, 10.1128/MCB.22.18.6458-6470.2002 · DOI
  11. Dial, 2003, Three conformational states of the p300 CH1 domain define its functional properties, Biochemistry, 42, 9937, 10.1021/bi034989o · DOI
  12. El-Deiry, 1993, WAF1, a potential mediator of p53 tumor suppression, Cell, 75, 817, 10.1016/0092-8674(93)90500-P · DOI · Paper page
  13. Fischle, 2003, Histones and chromatin cross-talk, Curr. Opin. Cell Biol., 15, 172, 10.1016/S0955-0674(03)00013-9 · DOI
  14. Foster, 1994, The ability of human papillomavirus E6 proteins to target p53 for degradation in vivo correlates with their ability to abrogate actinomycin D-induced growth arrest, J. Virol., 68, 5698, 10.1128/jvi.68.9.5698-5705.1994 · DOI · Paper page
  15. Georges, 2003, Tax recruitment of CBP/p300, via the KIX domain, reveals a potent requirement for acetyltransferase activity that is chromatin dependent and histone tail independent, Mol. Cell. Biol., 23, 3392, 10.1128/MCB.23.10.3392-3404.2003 · DOI
  16. Girdwood, 2003, p300 transcriptional repression is mediated by SUMO modification, Mol. Cell, 11, 1043, 10.1016/S1097-2765(03)00141-2 · DOI
  17. Hamiche, 1999, ATP-dependent histone octamer sliding mediated by the chromatin remodeling complex NURF, Cell, 97, 833, 10.1016/S0092-8674(00)80796-5 · DOI
  18. Harton, 2001, The histone acetyltransferase domains of CREB-binding protein (CBP) and p300/CBP-associated factor are not necessary for cooperativity with the class II transactivator, J. Biol. Chem., 276, 38715, 10.1074/jbc.M106652200 · DOI
  19. Hou, 2000, Alleviation of human papillomavirus E2-mediated transcriptional repression via formation of a TATA binding protein (or TFIID)-TFIIB-RNA Polymerase II-TFIIF preinitiation complex, Mol. Cell. Biol., 20, 113, 10.1128/MCB.20.1.113-125.2000 · DOI
  20. Inga, 2002, Differential transactivation by the p53 transcription factor is highly dependent on p53 level and promoter target sequence, Mol. Cell. Biol., 22, 8612, 10.1128/MCB.22.24.8612-8625.2002 · DOI
  21. Ito, 1999, ACF consists of two subunits, Acf1 and ISWI, that function cooperatively in the ATP-dependent catalysis of chromatin assembly, Genes Dev., 13, 1529, 10.1101/gad.13.12.1529 · DOI
  22. Jiang, 1998, Mutation of the Angelman ubiquitin ligase in mice causes increased cytoplasmic p53 and deficits of contextual learning and long-term potentiation, Neuron, 21, 799, 10.1016/S0896-6273(00)80596-6 · DOI · Paper page
  23. Kahyo, 2001, Involvement of PIAS1 in the sumoylation of tumor suppressor p53, Mol. Cell, 8, 713, 10.1016/S1097-2765(01)00349-5 · DOI
  24. Kanno, 2004, Selective recognition of acetylated histones by bromodomain proteins visualized in living cells, Mol. Cell, 13, 33, 10.1016/S1097-2765(03)00482-9 · DOI
  25. Kazemi, 2004, Control of α subunit of eukaryotic translation initiation factor 2 (eIF2α) phosphorylation by the human papillomavirus type 18 E6 oncoprotein, Mol. Cell. Biol., 24, 3415, 10.1128/MCB.24.8.3415-3429.2004 · DOI
  26. Koop, 2003, Histone H1 enhances synergistic activation of the MMTV promoter in chromatin, EMBO J., 22, 588, 10.1093/emboj/cdg052 · DOI
  27. Korenjak, 2004, Native E2F/RBF complexes contain Myb-interacting proteins and repress transcription of developmentally controlled E2F target genes, Cell, 119, 181, 10.1016/j.cell.2004.09.034 · DOI
  28. Kraus, 1999, Biochemical analysis of distinct activation functions in p300 that enhance transcription initiation with chromatin templates, Mol. Cell. Biol., 19, 8123, 10.1128/MCB.19.12.8123 · DOI
  29. Lau, 2000, p300/CBP-associated factor histone acetyltransferase processing of a peptide substrate. Kinetic analysis of the catalytic mechanism, J. Biol. Chem., 275, 21953, 10.1074/jbc.M003219200 · DOI
  30. Li, 1999, The human papilloma virus (HPV)-18 E6 oncoprotein physically associates with Tyk2 and impairs Jak-STAT activation by interferon-α, Oncogene, 18, 5727, 10.1038/sj.onc.1202960 · DOI · Paper page
  31. Liu, 1999, Multiple functions of human papillomavirus type 16 E6 contribute to the immortalization of mammary epithelial cells, J. Virol., 73, 7297, 10.1128/JVI.73.9.7297-7307.1999 · DOI · Paper page
  32. Lomvardas, 2002, Modifying gene expression programs by altering core promoter chromatin architecture, Cell, 110, 261, 10.1016/S0092-8674(02)00822-X · DOI
  33. Mal, 2001, A role for histone deacetylase HDAC1 in modulating the transcriptional activity of MyoD, EMBO J., 20, 1739, 10.1093/emboj/20.7.1739 · DOI
  34. Mantovani, 2001, The human papillomavirus E6 protein and its contribution to malignant progression, Oncogene, 20, 7874, 10.1038/sj.onc.1204869 · DOI
  35. Martinez-Campa, 2004, Precise nucleosome positioning and the TATA box dictate requirements for the histone H4 tail and the bromodomain factor Bdf1, Mol. Cell, 15, 69, 10.1016/j.molcel.2004.05.022 · DOI
  36. McMurray, 2004, Degradation of p53, not telomerase activation, by E6 is required for bypass of crisis and immortalization by human papillomavirus type 16 E6/E7, J. Virol., 78, 5698, 10.1128/JVI.78.11.5698-5706.2004 · DOI
  37. Mietz, 1992, The transcriptional transactivation function of wild-type p53 is inhibited by SV40 large T-antigen and by HPV-16 E6 oncoprotein, EMBO J., 11, 5013, 10.1002/j.1460-2075.1992.tb05608.x · DOI
  38. Näär, 1998, Chromatin, TAFs, and a novel multiprotein coactivator are required for synergistic activation by Sp1 and SREBP-1a in vitro, Genes Dev., 12, 3020, 10.1101/gad.12.19.3020 · DOI
  39. Owen-Hughes, 1999, Analysis of nucleosome disruption by ATP-driven chromatin remodeling complexes, Methods Mol. Biol., 119, 319
  40. Patel, 1999, The E6 protein of human papillomavirus type 16 binds to and inhibits co-activation by CBP and p300, EMBO J., 18, 5061, 10.1093/emboj/18.18.5061 · DOI · Paper page
  41. Pipas, 2001, Role of T antigen interactions with p53 in tumorigenesis, Semin. Cancer Biol., 11, 23, 10.1006/scbi.2000.0343 · DOI
  42. Ronco, 1998, Human papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor-3 and inhibits its transcriptional activity, Genes Dev., 12, 2061, 10.1101/gad.12.13.2061 · DOI · Paper page
  43. Scheffner, 1993, The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53, Cell, 75, 495, 10.1016/0092-8674(93)90384-3 · DOI · Paper page
  44. Schiltz, 1999, Overlapping but distinct patterns of histone acetylation by the human coactivators p300 and PCAF within nucleosomal substrates, J. Biol. Chem., 274, 1189, 10.1074/jbc.274.3.1189 · DOI
  45. Shimizu, 1997, Transcriptional repression at a distance through exclusion of activator binding in vivo, Proc. Natl. Acad. Sci. USA, 94, 790, 10.1073/pnas.94.3.790 · DOI
  46. Shang, 2000, Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription, Cell, 103, 843, 10.1016/S0092-8674(00)00188-4 · DOI
  47. Sherr, 2004, Principles of tumor suppression, Cell, 116, 235, 10.1016/S0092-8674(03)01075-4 · DOI
  48. Snowden, 2000, A novel transcriptional repression domain mediates p21WAF1/CIP1 induction of p300 transactivation, Mol. Cell. Biol., 20, 2676, 10.1128/MCB.20.8.2676-2686.2000 · DOI
  49. Somasundaram, 1997, Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21WAF1/CIP1, Nature, 389, 187, 10.1038/38291 · DOI
  50. Sterner, 2000, Acetylation of histones and transcription-related factors, Microbiol. Mol. Biol. Rev., 64, 435, 10.1128/MMBR.64.2.435-459.2000 · DOI
  51. Talis, 1998, The role of E6AP in the regulation of p53 protein levels in human papillomavirus (HPV)-positive and HPV-negative cells, J. Biol. Chem., 273, 6439, 10.1074/jbc.273.11.6439 · DOI
  52. Verma, 2004, The ubiquitin-conjugating enzyme UBCH7 acts as a coactivator for steroid hormone receptors, Mol. Cell. Biol., 24, 8716, 10.1128/MCB.24.19.8716-8726.2004 · DOI
  53. Wang, 2001, hADA3 is required for p53 activity, EMBO J., 20, 6404, 10.1093/emboj/20.22.6404 · DOI
  54. Wu, 1998, Properties of PC4 and RNA polymerase II complex in directing activated and basal transcription in vitro, J. Biol. Chem., 273, 12492, 10.1074/jbc.273.20.12492 · DOI
  55. Wu, 2001, TATA-binding protein-associated factors enhance the recruitment of RNA polymerase II by transcriptional activators, J. Biol. Chem., 276, 34235, 10.1074/jbc.M102463200 · DOI
  56. Wu, 1998, TAFII-independent activation mediated by human TBP in the presence of the positive cofactor PC4, EMBO J., 17, 4478, 10.1093/emboj/17.15.4478 · DOI
  57. Wu, 1999, Isolation of mouse TFIID and functional characterization of TBP and TFIID in mediating estrogen receptor and chromatin transcription, J. Biol. Chem., 274, 23480, 10.1074/jbc.274.33.23480 · DOI
  58. Wu, 2003, Human mediator enhances activator-facilitated recruitment of RNA polymerase II and promoter recognition by TATA-binding protein (TBP) independently of TBP-associated factors, Mol. Cell. Biol., 23, 6229, 10.1128/MCB.23.17.6229-6242.2003 · DOI
  59. Yamaguchi, 2002, Evidence that negative elongation factor represses transcription elongation through binding to a DRB sensitivity-inducing factor/RNA polymerase II complex and RNA, Mol. Cell. Biol., 22, 2918, 10.1128/MCB.22.9.2918-2927.2002 · DOI
  60. Zhou, 2002, Sp1 and AP2 regulate but do not constitute TATA-less human TAFII55 core promoter activity, Nucleic Acids Res., 30, 4145, 10.1093/nar/gkf537 · DOI

Cited by

See all 178

Metadata

Authors
Thomas, M. C., & Chiang, C.-M.
Venue
Molecular Cell
Publisher
Elsevier BV
Published
2005-01
Volume
17
Issue
2
Pages
251-264
ISSN
1097-2765
DOI
10.1016/j.molcel.2004.12.016
Cited by
178
References
2
Language
en
Licence
Funders
National Institutes of Health

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review